Servier is a privately held global pharmaceutical company with a focus on oncology, neuroscience, immuno-inflammation, cardiovascular diseases, and metabolism. Governed by a non-profit foundation, the company is committed to therapeutic progress to serve patient needs and operates in over 150 countries.

Servier Group

Servier Perú

Servier North East Africa

Servier Pakistan

Servier Afrique de l'Ouest et du Centre

Servier Philippines

Servier Ecuador

WeHealth™ Digital Medicine

SERVIER Deutschland GmbH

Servier Laboratories South Africa

Servier România

Servier Indonesia

Servier Pharmaceuticals

Servier NL

Servier Slovakia

Laboratoires Servier Algérie

Servier Maroc

Servier Bangladesh

Servier Srbija

施维雅中国

Servier Magyarország

Servier BeLux

Venixxa Canada

Servier Canada

Servier Brazil

Servier Mexico

Servier Australia

Servier India Private Limited

Servier Lithuania

Servier France

Servier Thailand

Servier CMO

Servier Türkiye

Servier Ukraine

Servier Egypt

SERVIER NIGERIA

Servier Tunisie

Servier (Suisse) S.A.

Servier Bulgaria

Servier Nordics

Servier Espana

Servier Colombia

Founded to serve health, Servier is a global group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. The 21,400 employees of the Group are committed to this shared vocation, source of inspiration every day. 
As a world leader in cardiology, Servier's ambition is to become a focused and innovative player in oncology by targeting hard-to-treat cancers. That is why the Group allocates over 50% of its R&D budget to developing targeted and innovative therapies in oncology. 
Neuroscience and immuno-inflammatory diseases are the future growth drivers. In these areas, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. 
To promote access to quality care for all at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, relying on strong brands in France, Eastern Europe, Brazil and Nigeria.
In all these areas, the Group includes the patient voice at each stage of the life cycle of a medicine. 
Headquartered in France, Servier relies on a strong geographical footprint in over 150 countries and achieved a revenue of €4.9 billion in 2022.

--
To report a suspected adverse event with a Servier drug, please visit servier.com

Servier

Our unwavering commitment to and with patients 🚀🔥 stands out as the meaning behind our vocation.

At Servier, we believe that working with patients at all stages of a medicine’s life cycle will lead to better patient care and support solutions throughout the disease journey.

We are pleased to share with you inspiring initiatives from our teams worldwide.
👀 Today, the spotlight is on Servier Germany 🇩🇪: SERVIER Deutschland GmbH launched a social-media communication campaign to support patients with depression in between their appointments with health care professionals. Our teams turned to four influencers, who suffer from depression, to test the program and share their thoughts on their Instagram accounts.

Congratulations 👏 to the teams involved in this initiative!

#patient #health #WeAreServier #MovedByYou

👋 Today is the International Day of Education! This day, proclaimed by the United Nations s in 2018, is aimed at celebrating the role of education in peace and development. 👨‍🏫👩‍🏫 Currently, 250 million children and youth are out of school, and 763 million adults are illiterate.

To mark this day, Mécénat Servier reaffirms its commitments to education. From the outset, Mécénat Servier has provided support to nonprofit organizations, including 1001mots and Enfants d'Asie in Vietnam, who are committed to making sure children have access to education.

According to Corinne Massin, Director of Corporate Philanthropy: 🗣 “By providing financial support to dedicated associations and enabling Servier Group teams to take part in solidarity initiatives, we want to give as many children as possible a chance to learn and thus gain access to employment and income."

Read more about Mécénat Servier’s commitments 👉 https://lnkd.in/eEtPgQ48

#IDE2024 #InternationalDayEducation #education #solidarity #MecenatServier #WeAreServier #MovedByYou

Our unwavering commitment 🚀🔥 to and with patients stands out as the meaning behind our vocation.

At Servier, we believe that working with patients at all stages of a medicine’s life cycle will lead to better patient care and support solutions throughout the disease journey.

We are pleased to share with you inspiring initiatives from our teams worldwide.
👀 Today, the spotlight is on Servier India Private Limited 🇮🇳: Through the initiative of Servier India teams, patients and doctors took part in a project to improve therapeutic adherence in patients with cardiovascular disease.
The goal? Identify barriers to adherence and lifestyle advice, as well as ways to improve doctor-patient communication, thereby encouraging patients to take their treatment correctly. 

Congratulations 👏 to the teams involved in this initiative!

#patient #health #WeAreServier #MovedByYou

🔬 Myelodysplastic Syndromes (MDS) present a complex challenge in healthcare. Affecting bone marrow, MDS leads to the production of abnormal blood cells and can progress to Acute Myeloid Leukemia if not diagnosed early. 

🌍 Globally, MDS affects an estimated 87,000 people annually, with a higher prevalence in those over 65. This underlines the importance of targeted research and early detection strategies, especially as our population ages.

🔎 Early diagnosis is crucial, as 30% of patients with MDS go on to develop Acute Myeloid Leukemia (AML). In this case, their life expectancy drops to less than two years.

🩺 At Servier, we're dedicated to meeting our patients’ needs. To achieve that, our mission focuses on pioneering therapeutic innovations aimed at treating challenging cancers, particularly blood cancers such as Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia, including Myelodysplastic Syndromes (MDS).

Learn more about MDS and AML at 👉 https://swll.to/nmFdmP

#WeAreServier #MDSAwareness #Oncology #PatientCare #ServierResearch #HealthcareInnovation

Our unwavering commitment to and with patients 🚀🔥 stands out as the meaning behind our vocation.

At Servier, we believe that working with patients at all stages of a medicine’s life cycle will lead to better patient care and support solutions throughout the disease journey.

We are pleased to share with you inspiring initiatives from our teams worldwide.
👀 Today, the spotlight is on Servier Poland 🇵🇱: Servier Polska has been awarded the Ewa Borek Leader of Patient Centricity prize by MY Patients Foundation for the work done to prevent cardiovascular disease, particularly through the “Servier for the Heart” campaign.

Our mobile cardiology clinic provided free preventive tests to over 50,500 patients across more than 120 Polish towns and cities.

Congratulations to the teams involved in this initiative!

#patient #health #WeAreServier #MovedByYou

COM:SERVIER

Servier Group

Financials Not Available